Evidence map›Paper›PMID 29018035›Full record

ReviewCirculation research2018

Trials and Tribulations of CETP Inhibitors.

Alan R Tall, Daniel J Rader

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 6 pooled it
26.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 6 syntheses or guidelines pooled it, 287 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alan R TallFrom the Division of Molecular Medicine, Department of Medicine, Columbia University, New York (A.R.T.); and Departments of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.J.R.) art1@columbia.edu.
Daniel J RaderFrom the Division of Molecular Medicine, Department of Medicine, Columbia University, New York (A.R.T.); and Departments of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.J.R.).
University of Pennsylvania · US

Funding

Cholesterol efflux, CHIP and inflammasome activationR01HL107653 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2011 to 2026
$7.7M
Discovery and Validation of Novel Loci Associated with HDL FunctionR01HL111398 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DANESH, JOHN NAVID, RADER, DANIEL JAMES · 2012 to 2016
$3.3M
NHLBI NIH HHS R01 HL107653NHLBI NIH HHS R01 HL111398
6 · The paper itself

Abstract

The development of CETP (cholesteryl ester transfer protein) inhibitors has had a long and difficult course with 3 compounds failing in phase III clinical trials. Finally, the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification) trial has shown that the CETP inhibitor anacetrapib decreased coronary heart disease when added to statin therapy. Although the result is different to earlier studies, this is likely related to the size and duration of the trial. The benefit of anacetrapib seems to be largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C. Although the magnitude of benefit for coronary heart disease appeared to be moderate, in part this may have reflected aspects of the trial design. Anacetrapib treatment was associated with a small increase in blood pressure, but was devoid of major side effects and was also associated with a small reduction in diabetes mellitus. Treatment with CETP inhibitors, either alone or in combination with statins, could provide another option for patients with coronary disease who require further reduction in LDL (low-density lipoprotein) and non-HDL-C.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLHumansLipoproteins, LDLOxazolidinonesRandomized Controlled Trials as TopicanacetrapibAnticholesteremic AgentsCETP protein, humanCholesterol Ester Transfer ProteinsCholesterol, HDLLipoproteins, LDLOxazolidinonesanacetrapibcoronary diseasedalcetrapibevacetrapibtorcetrapib

Identifiers

PMID29018035
PMCPMC5756107
OpenAlexW2764023940

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.